On Wednesday, Novo Nordisk A/S NVO launched NovoCare Pharmacy, a direct-to-patient supply service to enhance entry to Wegovy (semaglutide) for cash-paying sufferers.
This system presents all dosage strengths of the weight-loss treatment at a diminished value of $499 per thirty days for uninsured people or these whose insurance coverage doesn’t cowl weight problems remedies.
Final yr, Drugmaker Eli Lilly And Co LLY introduced a new web site permitting sufferers to get a prescription for weight reduction by means of a telehealth supplier, marking an business first.
This initiative follows the FDA’s declaration that the Wegovy scarcity has been resolved, making certain provide meets present and projected demand within the U.S.
Final week, the compounding teams Outsourcing Services Affiliation (OFA) and FarmaKeio Superior Customized Compounding filed a lawsuit difficult the FDA’s resolution to take away semaglutide from the drug scarcity listing.
Dave Moore, Government Vice President of U.S. Operations and International Enterprise Growth at Novo Nordisk, famous that whereas over 55 million Individuals have protection for weight administration remedies, 90% of insured Wegovy customers pay between $0 and $25 per thirty days.
Additionally Learn: AbbVie Turns into One other Massive Pharma To Enter Weight problems Therapy Race
NovoCare Pharmacy permits cash-paying sufferers to obtain house deliveries of prescribed Wegovy doses, facilitated by CenterWell Pharmacy, a six-time Specialty Pharmacy Affected person Alternative award winner. Sufferers additionally profit from refill reminders, profit verification, and stay help from NovoCare case managers.
The corporate says the service helps mitigate dangers related to compounded semaglutide merchandise, which the FDA and medical specialists have warned may pose security issues.
Final month, Eli Lilly launched 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, obtainable for $499 with the brand new Zepbound Self Pay Journey Program. Eli Lilly additionally diminished the value of the 2.5 mg and 5 mg vials.
These new choices can be found solely by means of LillyDirect Self-Pay Pharmacy Options, which permits a clear value by eradicating third-party provide chain entities and permitting sufferers to entry financial savings immediately outdoors of insurance coverage.
Worth Motion: NVO inventory is up 4.30% at $91.26 on the final examine on Wednesday.
Learn Subsequent:
Picture by Tobias Arhelger by way of Shutterstock
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
